Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2020

01-10-2020 | Parkinson's Disease | Review

Autonomic Dysfunction in Parkinson’s Disease

Author: Ronald F. Pfeiffer

Published in: Neurotherapeutics | Issue 4/2020

Login to get access

Abstract

Recognition of the importance of nonmotor dysfunction as a component of Parkinson’s disease has exploded over the past three decades. Autonomic dysfunction is a frequent and particularly important nonmotor feature because of the broad clinical spectrum it covers. Cardiovascular, gastrointestinal, urinary, sexual, and thermoregulatory abnormalities all can appear in the setting of Parkinson’s disease. Cardiovascular dysfunction is characterized most prominently by orthostatic hypotension. Gastrointestinal dysfunction can involve virtually all levels of the gastrointestinal tract. Urinary dysfunction can entail either too frequent voiding or difficulty voiding. Sexual dysfunction is frequent and frustrating for both patient and partner. Alterations in sweating and body temperature are not widely recognized but often are present. Autonomic dysfunction can significantly and deleteriously impact quality of life for individuals with Parkinson’s disease. Because effective treatment for many aspects of autonomic dysfunction is available, it is vitally important that assessment of autonomic dysfunction be a regular component of the neurologic history and exam and that appropriate treatment be initiated and maintained.
Appendix
Available only for authorised users
Literature
1.
Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002;8(4):277-284.PubMedCrossRef
2.
3.
Stanković I, Petrović I, Pekmezović T, et al. Longitudinal assessment of autonomic dysfunction in early Parkinson’s disease. Parkinsonism Relat Disord 2019;66:74-79.PubMedCrossRef
4.
De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol 2017;74(8):970-976.PubMedPubMedCentralCrossRef
5.
Tsiouris KM, Konitsiotis S, Koutsouris DD, Fotiadis DI. Prognostic factors of rapid symptoms progression in patients with newly diagnosed Parkinson’s disease. Artif Intell Med 2020;103:101807.PubMedCrossRef
6.
Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson’s disease. Mov Disord 2009;24(6):793-800.PubMedCrossRef
7.
Evatt ML, Chaudhuri KR, Chou KL, et al. Dysautonomia rating scales in Parkinson’s disease: sialorrhea, dysphagia, and constipation – critique and recommendations by Movement Disorders Task Force on Rating Scales for Parkinson’s Disease. Mov Disord 2009;24(5):635-646.PubMedPubMedCentralCrossRef
8.
Pavy-Le Traon A, Amarenco G, Duerr S, et al. The Movement Disorders Task Force review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011;26(11):1985-1992.PubMedCrossRef
9.
Pavy-Le Traon A, Cotterill N, Amarenco G, et al. Clinical rating scales for urinary symptoms in Parkinson’s disease: critique and recommendations. Mov Disord Clin Pract 2018;5(5):479-491.PubMedPubMedCentralCrossRef
10.
Driver-Dunckley ED, Zhang N, Shill HA, et al. Movement Disorders Society’s Unified Parkinson’s Disease Rating Scale and nonmotor scales in patients with Parkinson’s disease. Innov Clin Neurosci 2019;16(9-10):27-29.PubMedPubMedCentral
11.
Tanner CM, Kieburtz K, Galpern W, et al. Facilitating clinical research: the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson’s Disease Common Data Elements project. Parkinsonism Relat Disord 2012;18S2:S10-S11.CrossRef
12.
Goldstein DS. Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2003;2(11):669-676.PubMedCrossRef
13.
Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 2005;15(1):29-34.PubMedCrossRef
14.
Rascol O, Schelosky L. 123I-Metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord 2009;24(Suppl 2):S732-S741.PubMedCrossRef
15.
Goldstein DS, Holmes C, Bentho O, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008;14(8):600-607.PubMedPubMedCentralCrossRef
16.
Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 2012;18(5):494-500.PubMedCrossRef
17.
Haensch CA, Lerch H, Jörg J, Isenmann S. Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson’s disease. Parkinsonism Relat Disord 2009;15(2):134-137.PubMedCrossRef
18.
Katagiri A, Asahina M, Araki N, et al. Myocardial (123)I-MIBG uptake and cardiovascular autonomic function in Parkinson’s disease. Parkinsons Dis 2015;2015:805351.PubMedPubMedCentral
19.
Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21(2):69-72.PubMedCrossRef
20.
21.
Palma JA, Kaufmann H. Orthostatic hypotension in Parkinson disease. Clin Geriatr Med 2020;36:53-67.PubMedCrossRef
22.
Shaw BH, Garland EM, Black BK, et al. Optimal diagnostic thresholds for diagnosis of orthostatic hypotension with a “sit-to-stand test.” J Hypertens 2017;35(5):1019-1025.PubMedPubMedCentralCrossRef
23.
24.
Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017;264:1567-1582.PubMedPubMedCentralCrossRef
25.
Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RMA. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2011;17(10):724-729.PubMedPubMedCentralCrossRef
26.
27.
Strano S, Fanciulli A, Rizzo M, et al. Cardiovascular dysfunction in untreated Parkinson’s disease: a multi-modality assessment. J Neurol Sci 2016;370:251-255.PubMedCrossRef
28.
Senard JM, Raï S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;63(5):584-589.PubMedPubMedCentralCrossRef
29.
Merola A, Romagnolo A, Rosso M, et al. Orthostatic hypotension in Parkinson’s disease: does it matter if asymptomatic? Parkinsonism Relat Disord 2016;33:65-71.PubMedCrossRef
30.
31.
Rascol O, Perez-Lloret S, Damier P, et al. Falls in ambulatory non-demented patients with Parkinson’s disease. J Neural Transm (Vienna) 2015;122(10):1447-1455.CrossRef
32.
Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE. Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol 2016;15(9):954-966.PubMedCrossRef
33.
Rowell LB, Detry JM, Blackmon JR, Wyss C. Importance of the splanchnic vascular bed in human blood pressure regulation. J Appl Physiol 1972;32(2):213-220.PubMedCrossRef
34.
Figueroa JJ, Singer W, Sandroni P, et al. Effects of patient-controlled abdominal compression on standing systolic blood pressure in adults with orthostatic hypotension. Arch Phys Med Rehabil 2015;96(3):505-510.PubMedCrossRef
35.
36.
37.
Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K. Standing and supine blood pressure outcomes associated with droxidopa and midodrine in patients with neurogenic orthostatic hypotension: a Bayesian meta-analysis and mixed treatment comparison of randomized trials. Ann Pharmacother 2018;52(12):1182-1194.PubMedCrossRef
38.
McClellan KJ, Wiseman LR, Wilde MI. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 1998;12(1):76-86.PubMedCrossRef
39.
Kaufmann H, Norcliffe-Kaufmann L, Hewitt LA, Rowse GJ, White WB. Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. J Am Soc Hypertens 2016;10(10):819-826.PubMedCrossRef
40.
Kaufmann H. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn? Clin Auton Res 2017;27(Suppl 1):1-3.PubMedPubMedCentral
41.
McDonell KE, Shibao CA, Biaggioni I, Hartman A, Robertson D, Claasen DO. Cognitive and behavioral changes in patients treated with droxidopa for neurogenic orthostatic hypotension: a retrospective review. Cogn Behav Neurol 2019;32(3):179-184.PubMedPubMedCentralCrossRef
42.
43.
Cicconetti P, Ciotti V, Monteforte G, et al. Circadian blood pressure pattern and cognitive function in newly diagnosed older hypertensives. Blood Press 2003;12(3):168-174.PubMedCrossRef
44.
Routledge F, McFetridge-Durdle J. Nondipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 2007;6(1):9-26.PubMedCrossRef
45.
Fanciulli A, Jordan J, Biaggioni I, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS). Clin Auton Res 2018;28(4):355-362.PubMedPubMedCentralCrossRef
46.
Fanciulli A, Göbel G, Ndayisaba JP, et al. Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res 2016;26(2):97-105.PubMedCrossRef
47.
Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res 2016;26(1):15-21.PubMedCrossRef
48.
Biaggioni I. Orthostatic hypotension in the hypertensive patient. Am J Hypertens 2018;31(12):1255-1259.PubMedCrossRef
49.
Gamboa A, Shibao C, Diedrich A, et al. Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure. Hypertension 2008;51:1531-1536.PubMedPubMedCentralCrossRef
50.
Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord 1991;6(2):151-156.PubMedCrossRef
51.
Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007;69(4):333-341.PubMedCrossRef
52.
53.
Karakoc M, Yon MI, Cakmakli GY, et al. Pathophysiology underlying drooling in Parkinson’s disease: oropharyngeal bradykinesia. Neurol Sci 2016;37(12):1987-1991.PubMedCrossRef
54.
Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002;17(6):1318-1320.PubMedCrossRef
55.
56.
Jost WH, Friedman A, Michel O, et al. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism Relat Disord 2020;70:23-30.PubMedCrossRef
57.
Narayanaswami P, Geisbush T, Tarulli A, et al. Drooling in Parkinson’s disease: a randomized controlled trial of incobotulinum toxin A and a meta-analysis of botulinum toxins. Parkinsonism Relat Disord 2016;30:73-77.PubMedCrossRef
58.
Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 2004;62(1):37-40.PubMedCrossRef
59.
Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2011;17(1):10-15.PubMedCrossRef
60.
Kalf JG, de Swart BJM, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord 2012;18:311-315.PubMedCrossRef
61.
Jones CA, Ciucci MR. Multimodal swallowing evaluation with high-resolution manometry reveals subtle swallowing changes in early and mid-stage Parkinson disease. J Parkinsons Dis 2016;6(1):197-208.PubMedPubMedCentralCrossRef
62.
Paul BS, Singh T, Paul G, et al. Prevalence of malnutrition in Parkinson’s disease and correlation with gastrointestinal symptoms. Ann Indian Acad Neurol 2019;22(4):447-452.PubMedPubMedCentral
63.
Fabbri M, Coelho M, Abreu D, et al. Dysphagia predicts poor outcome in late-stage Parkinson’s disease. Parkinsonism Relat Disord 2019;64:73-81.PubMedCrossRef
64.
Buhmann C, Bihler M, Emich K, et al. Pill swallowing in Parkinson’s disease: a prospective study based on flexible endoscopic evaluation of swallowing. Parkinsonism Relat Disord 2019;62:51-56.PubMedCrossRef
65.
Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. In: Pfeiffer RF, Wszolek ZK, Ebadi M, eds. Parkinson’s disease. 2. Boca Raton: CRC Press; 2013: 309-326.
66.
Gross RD, Atwood CW Jr, Ross SB, Eichhorn KA, Olszewski JW, Doyle PJ. The coordination of breathing and swallowing in Parkinson’s disease. Dysphagia 2008;23(2):136-145.PubMedCrossRef
67.
Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson’s disease. A report of clinical experience at a single center. J Clin Gastroenterol 1994;19(1):11-16.PubMedCrossRef
68.
69.
70.
Menezes C, Melo A. Does levodopa improve swallowing dysfunction in Parkinson’s disease patients? J Clin Pharm Ther 2009;34(6):673-676.PubMedCrossRef
71.
Warnecke T, Suttrup I, Schröder JB, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-levodopa-test. Parkinsonism Relat Disord 2016;28:100-106.PubMedCrossRef
72.
Hirano M, Isono C, Fukuda K, Ueno S, Nakamura Y, Kusunoki S. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson’s disease. J Neurol Sci 2019;404:5-10.PubMedCrossRef
73.
Troche MS, Okun MS, Rosenbek JC, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology 2010:75(21):1912-1919.PubMedPubMedCentralCrossRef
74.
Byeon H. Effect of simultaneous application of postural techniques and expiratory muscle strength training on the enhancement of the swallowing function of patients with dysphagia caused by Parkinson’s disease. J Phys Ther Sci 2016;28(6):1840-1843.PubMedPubMedCentralCrossRef
75.
Curtis JA, Dakin AE, Troche MS. Respiratory-swallow coordination training and voluntary cough skill training: a single-subject treatment study in a person with Parkinson’s disease. J Speech Lang Hear Res 2020;63(2):472-486.PubMedCrossRef
76.
Miles A, Jardine M, Johnston F, de Lisle M, Friary P, Allen J. Effect of Lee Silverman Voice Treatment (LSVT-LOUD®) on swallowing and cough in Parkinson’s disease: a pilot study. J Neurol Sci 2017;383:180-187.PubMedCrossRef
77.
Kawaguchi M, Samura K, Miyagi Y, et al. The effects of chronic subthalamic stimulation on nonmotor symptoms in advanced Parkinson’s disease, revealed by an online questionnaire program. Acta Neurochir 2020;162:247-255.PubMedCrossRef
78.
Yin Z, Cao Y, Zheng S, et al. Persistent adverse effects following different targets and periods after bilateral deep brain stimulation in patients with Parkinson’s disease. J Neurol Sci 2018;393:116-127.PubMedCrossRef
79.
Khedr EM, Mohamed KO, Soliman RK, Hassan AMM, Rothwell JC. The effect of high-frequency repetitive transcranial magnetic stimulation on advancing Parkinson’s disease with dysphagia: double blind randomized clinical trial. Neurorehabil Neural Repair 2019;33(6):442-452.PubMedCrossRef
80.
Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson’s disease. N Engl J Med 2002;346(15):1174-1175.PubMedCrossRef
81.
Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov Disord 1996;11(1):53-58.PubMedCrossRef
82.
Pasricha PJ, Parkman HP. Gastroparesis: definitions and diagnosis. Gastroenterol Clin North Am 2015;44(1):1-7.PubMedCrossRef
83.
Heetun ZS, Quigley EM. Gastroparesis and Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 2012;18(5):433-440.PubMedCrossRef
84.
Su A, Gandhy R, Barlow C, Triadafilopuolos G. Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson’s disease who present with functional gastrointestinal symptoms. BMJ Open Gastroenterol 2017;4: https://​doi.​org/​10.​1136/​bmjgast-2017-000132.
85.
Tanaka Y, Kato T, Nishida H, et al. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson’s disease? An analysis using the 13C-acetate breath test. J Neurol 2011;258(3):421-426.PubMedCrossRef
86.
Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov Disord 1997;12(6):952-957.PubMedCrossRef
87.
Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol 2012;35(4):182-184.PubMedCrossRef
88.
Leelakanok K, Holcombe A, Schweizer ML. Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Clin Drug Investig 2016;36(2):97-107.PubMedCrossRef
89.
Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J 2015;128(1416):66-74.PubMed
90.
Asai H, Udaka F, Hirano M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson’s disease. Parkinsonism Relat Disord 2005;11:499-502.PubMedCrossRef
91.
Pinyopornpanish K, Soontornpun A, Kijdamrongthum P, Teeyasoontranon W, Angkurawaranon C, Thongsawat S. The effect of prucalopride on gastric emptying in Parkinson’s disease patients, a pilot randomized, open-label study. Digit Syst 2017;1(1):1-6.
92.
Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson’s disease patients. Parkinsonism Relat Disord 2011;17(4):285-287.PubMedCrossRef
93.
Triadafilopoulos G, Gandhy R, Barlow C. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson’s disease. Parkinsonism Relat Disord 2017;44:33-37.PubMedCrossRef
94.
Lembo A, Camilleri M, McCallum R, et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology 2016;151(1):87-96.e6.PubMedCrossRef
95.
Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology 2017;153:1240-1250.PubMedPubMedCentralCrossRef
96.
Davies KN, King D, Billington D, Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson’s disease. Postgrad Med J 1996;72:164-167.PubMedPubMedCentralCrossRef
97.
Dutkiewicz J, Szlufik S, Nieciecki M, et al. Small intestine dysfunction in Parkinson’s disease. J Neural Transm 2015;122:1659-1661.PubMedCrossRef
98.
Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 2013;28(9):1241-1249.PubMedCrossRef
99.
Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord 2014;20(5):535-540.PubMedCrossRef
100.
Niu XL, Liu L, Song ZX, et al. Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease. J Neural Transm (Vienna) 2016;123(12):1381-1386.CrossRef
101.
Vizcarra JA, Wilson-Perez HE, Fasano A, Espay AJ. Small intestinal bacterial overgrowth in Parkinson’s disease: tribulations of a trial. Parkinsonism Relat Disord 2018;54:110-112.PubMedCrossRef
102.
DiBaise JK, Crowell MD, Driver-Dunckley E, et al. Weight loss in Parkinson’s disease: no evidence for role of small intestinal bacterial overgrowth. J Parkinsons Dis 2018;8(4):571-581.PubMed
103.
104.
Pfeiffer RF. Management of autonomic dysfunction in Parkinson’s disease. Semin Neurol 2017;37:176-185.PubMedCrossRef
105.
Knudsen K, Krogh K, Østergaard K, Borghammer P. Constipation in Parkinson’s disease: subjective symptoms, objective markers, and new perspectives. Mov Disord 2017;32(1):94-105.PubMedCrossRef
106.
107.
Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009;73(21):1752-1758.PubMedPubMedCentralCrossRef
108.
Svensson E, Henderson VW, Borghammer P, Horváth-Puhó E, Sørensen HT. Constipation and risk of Parkinson’s disease: a Danish population-based cohort study. Parkinsonism Relat Disord 2016;28:18-22.PubMedCrossRef
109.
Lin CH, Lin JW, Liu YC, Chang CH, Wu RM. Risk of Parkinson’s disease following severe constipation: a nationwide population-based cohort study. Parkinsonism Relat Disord 2014;20(12):1371-1375.PubMedCrossRef
110.
Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015;30(12):1600-1609.PubMedCrossRef
111.
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease. A review. JAMA 2020;323(6):548-560.PubMedCrossRef
112.
Toebosch S, Tudyka V, Masclee A, Koek G. Treatment of recurrent sigmoid volvulus in Parkinson’s disease by percutaneous endoscopic colostomy. World J Gastroenterol 2012;18(40):5812-5815.PubMedPubMedCentralCrossRef
113.
Blackley S, Maguire C, Daniels T. Seven cases of sigmoid volvulus in Parkinson’s disease. J R Coll Physicians Edinb 2016;46(3):157-159.PubMedCrossRef
114.
Van Laar T, Boertien JM, Horta Herranz A. Faecal transplantation, pro- and prebiotics in Parkinson’s disease; hope or hype? J Parkinsons Dis 2019;9(s2):S371-S379.PubMedPubMedCentralCrossRef
115.
Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology 2016;87(12):1274-1280.PubMedCrossRef
116.
Freitas ME, Alqaraawi A, Lang AE, Liu LWC. Linaclotide and prucalopride for management of constipation in patients with parkinsonism. Mov Disord Clin Pract 2018;5(2):218-220.PubMedPubMedCentralCrossRef
117.
Omer A, Quigley EMM. An update on prucalopride in the treatment of chronic constipation. Ther Adv Gastroenterol 2017;10(11):877-887.CrossRef
118.
Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012;78(21):1650-1654.PubMedCrossRef
119.
Sakakibara R, Doi H, Sato M, et al. Nizatidine ameliorates slow transit constipation in Parkinson’s disease. J Am Geriatr Soc 2015;63(2):399-401.PubMedCrossRef
120.
Parkinson Study Group. A randomized trial of relamorelin for constipation in Parkinson’s disease (MOVE-PD): trial results and lessons learned. Parkinsonism Relat Disord 2017;37:101-105.CrossRef
121.
Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson’s disease. JAMA 1983;249(9):1148.PubMedCrossRef
122.
Pagano G, Tan EE, Haider JM, Bautista A, Tagliati M. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson’s disease. Parkinsonism Relat Disord 2015;21(2):120-125.PubMedCrossRef
123.
Chiu CM, Wang CP, Sung WH, Huang SF, Chiang SC, Tsai PY. Functional magnetic stimulation in constipation associated with Parkinson’s disease. J Rehabil Med 2009;41(13):1085-1089.PubMedCrossRef
124.
McClurg D, Walker K, Aitchison P, et al. Abdominal massage for the relief of constipation in people with Parkinson’s: a qualitative study. Parkinsons Dis 2016;2016:4842090.PubMedPubMedCentral
125.
Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol 2013;260(5):1332-1338.PubMedCrossRef
126.
Bassotti G, Maggio D, Battaglia E, et al. Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000;68(6):768-770.PubMedPubMedCentralCrossRef
127.
Tateno F, Sakakibara R, Yokoi Y, et al. Levodopa ameliorated anorectal constipation in de novo Parkinson’s disease: the QL-GAT study. Parkinsonism Relat Disord 2011;17(9):662-666.PubMedCrossRef
128.
Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol 1993;33(5):490-493.PubMedCrossRef
129.
Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am J Gastroenterol 2003;98(6):1439-1440.PubMedCrossRef
130.
Gourcerol G, Maltete D, Chastan N, Welter ML, Leroi AM, Derrey S. Does bilateral deep brain stimulation of the subthalamic nucleus modify ano-rectal motility in Parkinson’s disease? Results of a randomized cross-over study. Neuromodulation 2019;22(4):478-483.PubMedCrossRef
131.
McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson’s disease: prevalence aetiology and management. Parkinsonism Relat Disord 2017;35:8-16.PubMedCrossRef
132.
Kitta T, Yabe I, Kanno Y, et al. Long-term outcome of adenosine A2A receptor antagonist on lower urinary tract symptoms in male Parkinson disease patients. Clin Neuropharmacol 2018;41:98-102.PubMedPubMedCentralCrossRef
133.
Roy HA, Griffiths DJ, Aziz TZ, Green AL, Menke RAL. Investigation of urinary storage symptoms in Parkinson’s disease utilizing structural MRI techniques. NeurourolUrodyn 2019;38(4):1168-1175.
134.
Vurture G, Peyronnet B, Feigin A, et al. Outcomes of intradetrusor onabotulinum toxin A ijection in patients with Parkinson’s disease. NeurourolUrodyn 2018;37(8):2669-2677.
135.
Gubbiotti M, Conte A, Di Stasi SM, Tambasco N, Giannantoni A. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: a pilot study. Ther Adv Neurol Disord 2019;12:1-9.CrossRef
136.
Hajebrahimi S, Chapple CR, Pashazadeh F, Salehi-Pourmehr H. Management of neurogenic bladder in patients with Parkinson’s disease: a systematic review. NeurourolUrodyn 2019;38(1):31-62.
137.
Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22(11):1623-1629.PubMedCrossRef
138.
O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 2008;23(1):101-106.PubMedCrossRef
139.
Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis 2012;46(3):565-571.PubMedCrossRef
140.
Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, The Parkinson’s Disease Subcommittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. NeurourolUrodyn 2016;35(5):551-563.
141.
Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21(6):737-745.PubMedCrossRef
142.
Singer C, Moore H. Urological dysfunction. In: Pfeiffer RF, Wszolek ZK, Ebadi M, eds. Parkinson’s disease, 2 Boca Raton: CRC Press; 2013:327-341.
143.
Ragab MM, Mohammed ES. Idiopathic Parkinson’s disease patients at the urologic clinic. NeurourolUrodyn 2011;30(7):1258-1261.
144.
Vurture G, Peyronnet B, Palma J-A, et al. Urodynamic mechanisms underlying overactive bladder symptoms in patients with Parkinson disease. Int Neurourol J 2019;23(3):211-218.PubMedPubMedCentralCrossRef
145.
Moore H, Singer C. Urological dysfunction. In: Pfeiffer RF, Bodis-Wollner I, eds. Parkinson’s disease and nonmotor dysfunction, 2 New York: Humana Press; 2013:187-200.CrossRef
146.
Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson’s disease. J Urol 1983;129(1):80-83.PubMedCrossRef
147.
148.
Sakakibara R, Lee F-C, Suzuki H, Tateno F, Kishi M, Aiba Y. Parkinson’s disease and prostate enlargement: both contribute to overactive bladder in the elderly. Int J Urol 2018;25(11):982-983.PubMedCrossRef
149.
Vaughan CP, Burgio KL, Goode PS, et al. Behavioral therapy for urinary symptoms in Parkinson’s disease: a randomized clinical trial. NeurourolUrodyn 2019;38(6):1737-1744.
150.
McDonald C, Rees J, Winge K, Newton JL, Burn DJ. Bladder training for urinary tract symptoms in PD: a randomized controlled trial. Neurology 2020;94(13):e1427-e1433.PubMedPubMedCentralCrossRef
151.
Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008;62(11):1792-1800.PubMedPubMedCentralCrossRef
152.
153.
Zesiewicz TA, Evatt M, Vaughan CP, et al. Non-Motor Working Group of the Parkinson Study Group (PSG). Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord 2015;21(5):514-520.PubMedCrossRef
154.
Peyronnet B, Vurture G, Palma J-A, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord 2018;57:22-26.PubMedCrossRef
155.
156.
Kulaksizoglu H, Parman Y. Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson’s disease. Parkinsonism Relat Disord 2010;16(8):531-534.PubMedCrossRef
157.
Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol 2011;186(3):960-964.PubMedCrossRef
158.
159.
Mock S, Osborn DJ, Brown ET, et al. The impact of pallidal and subthalamic deep brain stimulation on urologic function in Parkinson’s disease. Neuromodulation 2016;19(7):717-723.PubMedPubMedCentralCrossRef
160.
161.
Stocchi F, Carbone A, Inghilleri M, et al. Urodynamic and neurophysiological evaluation in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997;62(5):507-511.PubMedPubMedCentralCrossRef
162.
Seth J, Rintoul-Hoad S, Sahai A. Urethral sphincter injection of botulinum toxin A: a review of its application and outcomes. Low Urin Tract Symptoms 2018;10(2):109-115.PubMedCrossRef
163.
van Hees PJ, van der Plas AA, van Ek GF, et al. Discussing sexuality with patients with Parkinson’s disease: a survey among Dutch neurologists. J Neural Transm (Vienna) 2017;124(3):361-368.CrossRef
164.
Jitkritsadakul O, Jagota P, Bhidayasiri R. Postural instability, the absence of sexual intercourse in the past month, and loss of libido are predictors of sexual dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2015;21(1):61-67.PubMedCrossRef
165.
Koller WC, Vetere-Overfield B, Williamson A, Busenbark K, Nash J, Parrish D. Sexual dysfunction in Parkinson’s disease. Clin Neuropharmacol 1990;13(5):461-463.PubMedCrossRef
166.
Pfeiffer RF. Gastrointestinal, urological, and sexual dysfunction in Parkinson’s disease. Mov Disord 2010;25(Suppl 1):S94-S97.PubMedCrossRef
167.
168.
Deng X, Xiao B, Li HH, et al. Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinson’s disease. J Neurol 2015;262(11):2433-2439.PubMedCrossRef
169.
Bronner G, Israeli-Korn S, Hassin-Baer S, Yahalom G. Acquired premature ejaculation in Parkinson’s disease and possible mechanisms. Int J Impot Res 2018;30(4):153-157.PubMedCrossRef
170.
Ferrucci R, Panzeri M, Ronconi L, et al. Abnormal sexuality in Parkinson’s disease: fact or fancy? J Neurol Sci 2016;369:5-10.PubMedCrossRef
171.
Zhao S, Wang J, Xie Q, et al. Parkinson’s disease is associated with risk of sexual dysfunction in men but not in women: a systematic review and meta-analysis. J Sex Med 2019;16:434-446.PubMedCrossRef
172.
173.
Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov Disord 2000;15(2):305-308.PubMedCrossRef
174.
Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71(3):371-374.PubMedPubMedCentralCrossRef
175.
Bernard BA, Verhagen Metman L, Levine L, Ouyang B, Leurgans S, Goetz CG. Sildenafil in the treatment of erectile dysfunction in Parkinson’s disease. Mov Disord Clin Pract 2016;4(3):412-415.PubMedPubMedCentralCrossRef
176.
Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol 2002;59(5):807-811.PubMedCrossRef
177.
Simonsen U, Comerma-Steffensen S, Andersson KE. Modulation of dopaminergic pathways to treat erectile dysfunction. Basic Clin Pharmacol Toxicol 2016;119(Suppl 3):63-74.PubMedCrossRef
178.
179.
Bronner G, Aharon-Peretz J, Hassin-Baer S. Sexuality in patients with Parkinson’s disease, Alzheimer’s disease, and other dementias. Handb Clin Neurol 2015;130:297-323.PubMedCrossRef
180.
Bronner G, Hassin-Baer S, Gurevich T. Sexual preoccupation behavior in Parkinson’s disease. J Parkinsons Dis 2017;7(1):175-182.PubMedCrossRef
181.
Aquino CC, Mestre T, Lang AE. Restless genital syndrome in Parkinson disease. JAMA Neurol 2014;71(12):1559-1561.PubMedCrossRef
182.
Lefaucheur R, Berthelot L, Sénant J, Borden A, Maltête D. Acute genital pain during non-motor fluctuations improved by apomorphine. Mov Disord 2013;28(5):687-688.PubMedCrossRef
183.
Skorvanek M, Bhatia KP. The skin and Parkinson’s disease: review of clinical, diagnostic, and therapeutic issues. Mov Disord Clin Pract 2016;4(1):21-31.176.PubMedPubMedCentralCrossRef
184.
185.
Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord 2015;30(2):229-237.PubMedCrossRef
186.
187.
Beach TG, Adler CH, Sue LI, et al; Arizona Parkinson’s Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119(6):689-702.PubMedPubMedCentralCrossRef
188.
Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014;29(8):1010-1018.PubMedCrossRef
189.
Ramirez-Zamora A, Smith H, Youn Y, Durphy J, Shin DS, Pilitsis JG. Hyperhidrosis associated with subthalamic deep brain stimulation in Parkinson’s disease: insights into central autonomic functional anatomy. J Neurol Sci 2016;366:59-64.PubMedCrossRef
190.
191.
Shindo K, Kobayashi F, Miwa M, Nagasaka T, Takiyama Y, Shiozawa Z. Temporal prolongation of decreased skin blood flow causes cold limbs in Parkinson’s disease. J Neural Transm (Vienna) 2013;120(3):445-451.CrossRef
192.
Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976;26(5):423-429.PubMedCrossRef
193.
De Marinis M, Stocchi F, Testa SR, De Pandis F, Agnoli A. Alterations of thermoregulation in Parkinson’s disease. Funct Neurol 1991;6(3):279-283.PubMed
194.
195.
Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson’s disease. Mov Disord 2003;18(12):1459-1463.PubMedCrossRef
196.
Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 2009;66(6):742-750.PubMedPubMedCentralCrossRef
197.
Pursiainen V, Haapaniemi TH, Korpelainen JT, Sotaniemi KA, Myllylä VV. Sweating in Parkinsonian patients with wearing-off. Mov Disord 2007;22(6):828-832.PubMedCrossRef
198.
Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinson’s disease: treatment and relation to plasma levodopa profile. Ann Neurol 1995;37(1):120-122.PubMedCrossRef
199.
van Wamelen DJ, Leta V, Podlewska AM, et al. Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson’s disease. J Neurol 2019;266:1736-1742.PubMedPubMedCentralCrossRef
200.
Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson’s disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 1991;151(4):794-796.PubMedCrossRef
201.
Serrano-Duenas M. Neuroleptic malignant syndrome-like, or – dopaminergic malignant syndrome – due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord 2003;9(3):175-178.PubMedCrossRef
202.
Ladha SS, Walker R, Shill HA. Case of neuroleptic malignant-like syndrome precipitated by abrupt fava bean discontinuance. Mov Disord 2005;20(5):630-631.PubMedCrossRef
203.
Bonnici A, Ruiner CE, St-Laurent L, Hornstein D. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay. Ann Pharmacother 2010;44(9):1504-1507.PubMedCrossRef
204.
Whitman CB, Ablordeppy E, Taylor B. Levodopa withdrawal presenting as fever in a critically ill patient receiving concomitant enteral nutrition. J Pharm Pract 2016;29(6):574-578.PubMedCrossRef
205.
206.
Trachani E, Constantoyannis C, Sirrou V, Kefalopoulou Z, Markaki E, Chroni E. Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson’s disease. Clin Neurol Neurosurg 2010;112(3):213-217.PubMedCrossRef
207.
Sanghera MK, Ward C, Stewart RM, Mewes K, Simpson RK, Lai EC. Alleviation of drenching sweats following subthalamic deep brain stimulation in a patient with Parkinson’s disease – a case report. J Neurol Sci 2009;285(1-2):246-249.PubMedCrossRef
Metadata
Title
Autonomic Dysfunction in Parkinson’s Disease
Author
Ronald F. Pfeiffer
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
Neurotherapeutics / Issue 4/2020
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-020-00897-4

Other articles of this Issue 4/2020

Neurotherapeutics 4/2020 Go to the issue

Review

Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies

Review

Management of psychiatric disorders in Parkinson’s disease

Original Article

Neuroprotective Activities of Long-Acting Granulocyte–Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice

Original Article

Pituitary Adenylate Cyclase-Activating Polypeptide Attenuates Brain Edema by Protecting Blood–Brain Barrier and Glymphatic System After Subarachnoid Hemorrhage in Rats

Original Article

Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models

Original Article

Administration of FK506 from Late Stage of Disease Prolongs Survival of Human Prion-Inoculated Mice